Colorado is currently home to 1805 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
NCT06343779
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
04/16/2025
Locations: Study Site, Colorado Springs, Colorado
Conditions: Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
Register for Updates
Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP
NCT05972889
Recruiting
This is a prospective, sham-controlled, randomized, single-blinded, multi-center study comparing two different modes of the NexWave device, transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC), with an identical non-functioning NexWave sham device or self-defined standard of care for improvement of pain intensity of non-specific CLBP.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/16/2025
Locations: DBPS Research, Greenwood Village, Colorado
Conditions: Non-Specific Chronic Lower Back Pain
Register for Updates
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
04/16/2025
Locations: Denver Neurological Research, Denver, Colorado
Conditions: Alzheimer Disease
Register for Updates
A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT03972657
Recruiting
The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in com... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Sarah Cannon Research Institute (SCRI), Denver, Colorado
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Register for Updates
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
NCT03033992
Recruiting
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum 2).
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
04/16/2025
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
VISN 19 MIRECC Research Database
NCT01334476
Recruiting
The VISN 19 MIRECC is involved in research concerned with suicide prevention in high risk populations (e.g., history of traumatic brain injury, post-traumatic stress disorder); Recruitment for future studies will continue with a similar focus. The aim of this protocol is for the VISN 19 MIRECC Research Database (V19-MRD), to have a data repository of participants for possible recruitment from other studies being conducted at the VISN 19 MIRECC. The VISN 19 MIRECC conducts numerous research proje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: VA Eastern Colorado Health Care System, Denver, Colorado
Conditions: Demographic Data, History of Medical and Mental Health, History of Combat Experience, History of Suicide, Imaging Results
Register for Updates
Testing the Engaged Approach to Lung Cancer Screening
NCT06327074
Recruiting
The goal of this study is to assess feasibility and acceptability of the Engaged Approach to Lung Cancer Screening (EA-LCS) in diverse lung cancer screening (LCS) programs operating in a variety of geographic regions across Colorado and the US.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Colorado Hospital, Denver, Colorado
Conditions: Lung Cancer
Register for Updates
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
NCT06211335
Recruiting
This phase Ib trial tests the safety, side effects and how well losartan, pembrolizumab and stereotactic body radiation therapy (SBRT) for the treatment of patients with head and neck squamous cell carcinoma that has come back to nearby tissue or lymph node after a period of improvement (locally recurrent), that has not responded to previous treatment (refractory) or that has spread from where it first started to multiple other placed in the body (oligometastatic). Losartan is a drug used to tre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Colorado Denver | Anschutz Medical Campus, Aurora, Colorado
Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
Register for Updates
Telehealth Delivered Home-based Walking for Vets With Peripheral Artery Disease
NCT06033924
Recruiting
Walking is beneficial for adults with peripheral arterial disease. Benefits include the ability to walk for longer periods and general well being (quality of life). This study will look at two types of delivery methods for a home-based walking program. The walking program includes step count goals, information on healthy walking and motivational messages. The two delivery methods include a web-based delivery and an telehealth delivery. Participants are randomized to either one of the delivery me... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/15/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado
Conditions: Peripheral Artery Disease
Register for Updates
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Colorado Retina Associates, Lakewood, Colorado
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates
Transfemoral Osseointegrated Prosthesis Limb-Load Symmetry Training
NCT05695911
Recruiting
This randomized controlled trial (n=25 enrolled, n=15 expected to complete) will 1) determine the feasibility of a 40-week limb-load biofeedback training intervention, 2) determine if there is an intervention signal of efficacy, and 3) identify functional movement priorities for people with transfemoral osseointegrated (OI) prostheses. A limb-load biofeedback training group (EXP (n=10)) will be compared to a standard of care attention-control group without limb-load biofeedback training (CTL (n=... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: CU Physical Therapy, Aurora, Colorado
Conditions: Amputation, Transfemoral Amputation, Osseointegration
Register for Updates
Liver Disease in Urea Cycle Disorders
NCT04612764
Recruiting
This is a multi-center, cross-sectional study to assess risk for liver fibrosis and hepatic injury in individuals with urea cycle disorders (UCDs) using serum biomarkers, Fibroscan, and MRE. This study will be conducted at 5 sites of the Urea Cycle Disorders Consortium: Baylor College of Medicine in Houston, TX, Seattle Children's Hospital in Seattle, WA, Children's Hospital Colorado in Aurora, CO, Children's Hospital of Philadelphia in Philadelphia, PA, and Children's National Medical Center in... Read More
Gender:
ALL
Ages:
Between 6 years and 65 years
Trial Updated:
04/15/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency, ASL Deficiency, Argininosuccinic Aciduria, ASS Deficiency, Hyperargininemia
Register for Updates